2025 Q3 -tulosraportti
38 päivää sitten33 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
63 076
Myynti
Määrä
47 073
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 175 | - | - | ||
| 62 | - | - | ||
| 1 161 | - | - | ||
| 167 | - | - | ||
| 6 353 | - | - |
Ylin
3,16VWAP
Alin
2,955VaihtoMäärä
3,7 1 221 718
VWAP
Ylin
3,16Alin
2,955VaihtoMäärä
3,7 1 221 718
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11. | |
| 2025 Q2 -tulosraportti | 22.8. | |
| 2025 Q1 -tulosraportti | 19.5. | |
| 2024 Q4 -tulosraportti | 7.2. | |
| 2024 Q3 -tulosraportti | 7.11.2024 |
Datan lähde: FactSet, Quartr
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3.12.Nice news today Wednesday morning : ASCELIA PHARMA: CONFIDENT WITH PROCESS LEADS TO PARTNERSHIP AGREEMENT – FOUC today at 09:09 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) Ascelia Pharma feels confident that they can reach a partnership agreement for the contrast agent candidate Orviglance. "We are very confident that we have a process that will lead to a good agreement," said Andreas Norlin, Head of Research at Ascelia Pharma, during his presentation at Redeye's Life Science day on Wednesday. He added that "we are very confident that we have a process that will lead to a good agreement". Andreas Norlin emphasizes that a potential partnership for Orviglance "is an incredibly important issue for everyone involved". The US drug agency FDA has set a target date for final approval decision to July 3, 2026, a so-called PDUFA date, for Orviglance. Orviglance has been granted orphan drug status by the US drug agency FDA for use as a contrast agent for MRI examination of the liver in patients with severely impaired kidney function.
·3.12. · MuokattuWith a partner agreement secured soon and a final approval of Orviglance in July 2026, I believe we can also aim for 15 - and perhaps even higher :) :) It would really be stupid to sell out now. This rise today is only just the beginning of something really big :)
·26.11.Will we soon see a bit of an upturn in this stock? ☺️🙏
·29.11.I don't think we will end up that far. What one is waiting for is a partner and I am quite confident that a partner will come. Then, whether it comes this quarter or during Q1 (2026), no one knows. Unfortunately, it's small investors who get tired and sell off at a loss because it has dropped 10-30 percent, to avoid losing even more, even though they don't understand that within biotech, a PM can give a share price boost of 100-300 percent. In this window from an FDA acceptance to an approval, a lot can happen. Then I have studied the share price a bit and in my opinion, it doesn't take much for it to take off.
·15.11.Ascelia Pharma announces FDA's acceptance of Orviglance's New Drug Application for review 15.11.2025, 10.15 0 likes 0 dislikes Ascelia Pharma Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the lives of people living with rare cancer diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Orviglance® for review. The FDA has set an action date of 3. July 2026 under the Prescription Drug User Fee Act (PDUFA). Through its 'day 74 letter', the FDA has confirmed its acceptance of the NDA application for Orviglance and continuation of the review, aiming for a decision by 3. July 2026 as the PDUFA date. "This milestone represents another important step towards our goal of making Orviglance available to cancer patients with impaired renal function. We look forward to continuing to work with the FDA throughout the review process," says Magnus Corfitzen, CEO of Ascelia Pharma. "The FDA's application acceptance is also important for our discussions with potential commercialization partners."- ·4.11.Is anyone positive about tomorrow?
·4.11.No, not really. Expect a rather neutral report without surprises. The primary trigger I'm waiting for is a partner. If the partnership agreement is reasonably good, there's a lot to gain here going forward. FDA is of course also a trigger, but there's still some time until the final answer. - ·26.10.Ascelia Pharma – Presentation of interim Q3 2025 report By HC Andersen Capital 06.11.2025, 12.00 https://www.inderes.dk/videos/ascelia-pharma-presentation-of-interim-q3-2025-report
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q3 -tulosraportti
38 päivää sitten33 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3.12.Nice news today Wednesday morning : ASCELIA PHARMA: CONFIDENT WITH PROCESS LEADS TO PARTNERSHIP AGREEMENT – FOUC today at 09:09 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) Ascelia Pharma feels confident that they can reach a partnership agreement for the contrast agent candidate Orviglance. "We are very confident that we have a process that will lead to a good agreement," said Andreas Norlin, Head of Research at Ascelia Pharma, during his presentation at Redeye's Life Science day on Wednesday. He added that "we are very confident that we have a process that will lead to a good agreement". Andreas Norlin emphasizes that a potential partnership for Orviglance "is an incredibly important issue for everyone involved". The US drug agency FDA has set a target date for final approval decision to July 3, 2026, a so-called PDUFA date, for Orviglance. Orviglance has been granted orphan drug status by the US drug agency FDA for use as a contrast agent for MRI examination of the liver in patients with severely impaired kidney function.·3.12. · MuokattuWith a partner agreement secured soon and a final approval of Orviglance in July 2026, I believe we can also aim for 15 - and perhaps even higher :) :) It would really be stupid to sell out now. This rise today is only just the beginning of something really big :)
- ·26.11.Will we soon see a bit of an upturn in this stock? ☺️🙏·29.11.I don't think we will end up that far. What one is waiting for is a partner and I am quite confident that a partner will come. Then, whether it comes this quarter or during Q1 (2026), no one knows. Unfortunately, it's small investors who get tired and sell off at a loss because it has dropped 10-30 percent, to avoid losing even more, even though they don't understand that within biotech, a PM can give a share price boost of 100-300 percent. In this window from an FDA acceptance to an approval, a lot can happen. Then I have studied the share price a bit and in my opinion, it doesn't take much for it to take off.
- ·15.11.Ascelia Pharma announces FDA's acceptance of Orviglance's New Drug Application for review 15.11.2025, 10.15 0 likes 0 dislikes Ascelia Pharma Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the lives of people living with rare cancer diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Orviglance® for review. The FDA has set an action date of 3. July 2026 under the Prescription Drug User Fee Act (PDUFA). Through its 'day 74 letter', the FDA has confirmed its acceptance of the NDA application for Orviglance and continuation of the review, aiming for a decision by 3. July 2026 as the PDUFA date. "This milestone represents another important step towards our goal of making Orviglance available to cancer patients with impaired renal function. We look forward to continuing to work with the FDA throughout the review process," says Magnus Corfitzen, CEO of Ascelia Pharma. "The FDA's application acceptance is also important for our discussions with potential commercialization partners."
- ·4.11.Is anyone positive about tomorrow?·4.11.No, not really. Expect a rather neutral report without surprises. The primary trigger I'm waiting for is a partner. If the partnership agreement is reasonably good, there's a lot to gain here going forward. FDA is of course also a trigger, but there's still some time until the final answer.
- ·26.10.Ascelia Pharma – Presentation of interim Q3 2025 report By HC Andersen Capital 06.11.2025, 12.00 https://www.inderes.dk/videos/ascelia-pharma-presentation-of-interim-q3-2025-report
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
63 076
Myynti
Määrä
47 073
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 175 | - | - | ||
| 62 | - | - | ||
| 1 161 | - | - | ||
| 167 | - | - | ||
| 6 353 | - | - |
Ylin
3,16VWAP
Alin
2,955VaihtoMäärä
3,7 1 221 718
VWAP
Ylin
3,16Alin
2,955VaihtoMäärä
3,7 1 221 718
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11. | |
| 2025 Q2 -tulosraportti | 22.8. | |
| 2025 Q1 -tulosraportti | 19.5. | |
| 2024 Q4 -tulosraportti | 7.2. | |
| 2024 Q3 -tulosraportti | 7.11.2024 |
Datan lähde: FactSet, Quartr
2025 Q3 -tulosraportti
38 päivää sitten33 min
Uutiset ja analyysit
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
| Seuraava tapahtuma | |
|---|---|
| 2025 Q4 -tulosraportti | 5.2.2026 |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 Q3 -tulosraportti | 6.11. | |
| 2025 Q2 -tulosraportti | 22.8. | |
| 2025 Q1 -tulosraportti | 19.5. | |
| 2024 Q4 -tulosraportti | 7.2. | |
| 2024 Q3 -tulosraportti | 7.11.2024 |
Datan lähde: FactSet, Quartr
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3.12.Nice news today Wednesday morning : ASCELIA PHARMA: CONFIDENT WITH PROCESS LEADS TO PARTNERSHIP AGREEMENT – FOUC today at 09:09 ∙ Nyhetsbyrån Direkt STOCKHOLM (Nyhetsbyrån Direkt) Ascelia Pharma feels confident that they can reach a partnership agreement for the contrast agent candidate Orviglance. "We are very confident that we have a process that will lead to a good agreement," said Andreas Norlin, Head of Research at Ascelia Pharma, during his presentation at Redeye's Life Science day on Wednesday. He added that "we are very confident that we have a process that will lead to a good agreement". Andreas Norlin emphasizes that a potential partnership for Orviglance "is an incredibly important issue for everyone involved". The US drug agency FDA has set a target date for final approval decision to July 3, 2026, a so-called PDUFA date, for Orviglance. Orviglance has been granted orphan drug status by the US drug agency FDA for use as a contrast agent for MRI examination of the liver in patients with severely impaired kidney function.·3.12. · MuokattuWith a partner agreement secured soon and a final approval of Orviglance in July 2026, I believe we can also aim for 15 - and perhaps even higher :) :) It would really be stupid to sell out now. This rise today is only just the beginning of something really big :)
- ·26.11.Will we soon see a bit of an upturn in this stock? ☺️🙏·29.11.I don't think we will end up that far. What one is waiting for is a partner and I am quite confident that a partner will come. Then, whether it comes this quarter or during Q1 (2026), no one knows. Unfortunately, it's small investors who get tired and sell off at a loss because it has dropped 10-30 percent, to avoid losing even more, even though they don't understand that within biotech, a PM can give a share price boost of 100-300 percent. In this window from an FDA acceptance to an approval, a lot can happen. Then I have studied the share price a bit and in my opinion, it doesn't take much for it to take off.
- ·15.11.Ascelia Pharma announces FDA's acceptance of Orviglance's New Drug Application for review 15.11.2025, 10.15 0 likes 0 dislikes Ascelia Pharma Ascelia Pharma AB (publ) (ticker: ACE), a biotech company focused on improving the lives of people living with rare cancer diseases, announced today that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Orviglance® for review. The FDA has set an action date of 3. July 2026 under the Prescription Drug User Fee Act (PDUFA). Through its 'day 74 letter', the FDA has confirmed its acceptance of the NDA application for Orviglance and continuation of the review, aiming for a decision by 3. July 2026 as the PDUFA date. "This milestone represents another important step towards our goal of making Orviglance available to cancer patients with impaired renal function. We look forward to continuing to work with the FDA throughout the review process," says Magnus Corfitzen, CEO of Ascelia Pharma. "The FDA's application acceptance is also important for our discussions with potential commercialization partners."
- ·4.11.Is anyone positive about tomorrow?·4.11.No, not really. Expect a rather neutral report without surprises. The primary trigger I'm waiting for is a partner. If the partnership agreement is reasonably good, there's a lot to gain here going forward. FDA is of course also a trigger, but there's still some time until the final answer.
- ·26.10.Ascelia Pharma – Presentation of interim Q3 2025 report By HC Andersen Capital 06.11.2025, 12.00 https://www.inderes.dk/videos/ascelia-pharma-presentation-of-interim-q3-2025-report
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
63 076
Myynti
Määrä
47 073
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 175 | - | - | ||
| 62 | - | - | ||
| 1 161 | - | - | ||
| 167 | - | - | ||
| 6 353 | - | - |
Ylin
3,16VWAP
Alin
2,955VaihtoMäärä
3,7 1 221 718
VWAP
Ylin
3,16Alin
2,955VaihtoMäärä
3,7 1 221 718
Välittäjätilasto
Dataa ei löytynyt